Immuron Ltd — Regulatory Filings 2006

Jan 17, 2006

January 18th, 2006

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Please find herewith a company announcement "Travelan Potentially Identified for Additional Therapeutic Indications" for release and distribution to the market immediately.

Yours sincerely

CONOR GRAHAM Managing Director & CEO

indications identified

Anadis is now investigating the use of Travelan for additional gastrointestinal therapeutic indications as a result of positive clinical feedback from a number of healthcare providers including medical specialists.

Reports to the company indicate that a number of patients with a range of gastrointestinal conditions, including irritable bowel syndrome (IBS) and ulcerative colitis, have experienced an improvement in some their symptoms (e.g. diarrhoea) whilst they have been taking Travelan to reduce their risk of travellers' diarrhoea.

Diarrhoea or increased stool frequency is prevalent in many lower gastrointestinal tract conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease.

It is important to note that Travelan is already available as an over-the-counter (OTC) in pharmacies nationally and would be immediately available for potential patients.

IBD Pilot Study

After review, of the clinical evidence, the Anadis Scientific Subcommittee has agreed to conduct a single arm, uncontrolled pilot study in patients with stable IBD in whom Travelan will be added to their current treatment. Any beneficial therapeutic effect of Travelan will be assessed through the use of widely accepted disease activity markers.

Scientific basis for Travelan in IBD

The scientific basis for using Travelan as a therapy in IBD relates to the antibodies from hyper-immune colostrum (harvested from dairy cows, vaccinated with Anadis's patented vaccine) being able to bind some of the bacterial products which may be involved in the persistent inflammation that occurs in these conditions.

About Inflammatory Bowel Disease: (IBD)

Inflammatory bowel disease is the collective term given to two conditions, namely ulcerative colitis and Crohn's disease. These two disorders, primarily of the lower gastrointestinal tract (large bowel or colon) are characterised by inflammation of the intestine resulting in abdominal pain, diarrhoea (often bloody) and weight loss. The cause of both conditions is unknown although there is increasing evidence that dysfunction between the patients' immune system and the gut flora may play a role in continuing disease activity.

Currently there are over 70,000 people with IBD in Australia, while between 1 and 1.4 million people in the United States and 2.2 million people in Europe suffer from these diseases.[1]

For more information about IBD visit www.thegutsygroup.com.au/

Reference:

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004 May;126(6):1504-17.

Current application for Travelan - Travellers' Diarrhoea

Travellers' diarrhoea is described as the number one health problem for international travellers, in terms of frequency and economic impact. Travellers' diarrhoea is normally accompanied by other clinical features such as nausea, bloating, abdominal cramps and fever. Travelan significantly reduces the risk of being affected in the first instance.

Travelan

Travelan - Anadis's lead product - is a revolutionary over-the-counter (OTC) preparation scientifically and clinically proven to significantly reduce the risk of getting the medical condition known as travellers' diarrhoea. Travelan is high in antibodies that bind to certain intestinal bacteria and bacterial by-products, and is not an antibiotic preparation.

Travelan, a natural, clinically proven therapy is prepared from bovine colostrum from cows hyper-immunized against the 13 strains of E, coli that are the most common cause of travellers' diarrhoea.

These further gastrointestinal indications represent an additional potential application for Travelan in the field of gastrointestinal health in the non-travel market.

International opportunities for Travelan

Anadis has recently been given a "green light" to sell Travelan in the US (see announcement Travelan receives Green Light to enter US market - 12^th October 2005). and is currently in discussions with prospective partners in the US market to begin sales of Travelan at the earliest opportunity.

Anadis has appointed Baralex Inc. / Valeo Pharma as Canadian pharmaceutical distributor for Travelan. Registration and the distribution agreement and are set for completion in late January 2006. First sales of Travelan into the Canadian market anticipated to begin February / March 2006.

Anadis is in the process of negotiating other international distribution and registration arrangements in markets including Singapore, Hong Kong, India, Thailand, Taiwan, Malaysia, United Kingdom, Europe and South Africa.

For more information about Travelan visit www.travelan.com.au

About Anadis Limited:

Anadis, a Melbourne based Biopharmaceutical Company, focused on Nutraceutical and Pharmaceutical product development. Anadis is currently also in the process of commercialising EV-71 - a bioactive protein based product against Enterovirus 71, a debilitating polio like disease affecting children in Taiwan and other parts of Asia.

A set of Bio-Defence/Respiratory Protection technologies where it has been shown that Anthrax lethal toxin can be 100% neutralized by Anadis' bovine colostrum derived antibodies. This project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma.

Bio-Shield 10 a range of "bioshielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market, and research has also begun into an Immune Stimulating Infant Formula initially for the Asian market.

Pyloran, which has been clinically proven to reduce levels of bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine.

For further information, please contact:

Conor Graham - Chief Executive Officer

Email: conor.g@anadis.com.au $+61393586388$

Dr Grant Rawlin - General Manager R&D

Email grant.r@anadis.com.au $+61393586388$

Arie Nudel – Investor Relations Email: arie.n@anadis.com.au $+61393586388$

Visit our websites: www.anadis.com.au and www.travelan.com.au

Anadis - Delivering On The Promise Of Biotechnology